
What is claimed is:

1. A pharmaceutical composition ~~for treating a subject suffering from androgen receptor associated medical condition,~~ comprising:

a compound selected from the group consisting of a compound according to formula VI ~~and formula VII~~:




VI

wherein $R_1$ and $R_2$ are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;


L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is ~~-H,~~ -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein $R_3$ and $R_4$ are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl ~~moiety,~~ or a cycloalkyl, or $R_3$ and $R_4$ together form a heterocyclic ~~ring~~; or Z is COOR wherein R is -H, $-CH_3$, or a cycloalkyl;

X is a halo ~~-F, -Cl, or -Br~~;

Y is ~~H, a~~n ~~short~~ alkyl ~~$C_{1-3}$~~, or ~~-F, Cl, Br~~a halo;

a compound~~and~~ according to formula VII:




VII

~~Wherein~~ wherein $R_1$ and $R_2$ are each independently ~~mono- or di-substituted groups, such as~~selected from a methoxy group ~~(-$OCH_3$)~~, a hydroxyl group ~~(-OH)~~, ~~or~~ and an alkyl sulfonyl group~~, such as -$OSO_2C_2H_5$; $R_1$ and $R_2$ could be the same or different~~;

L is a carbonyl, alkylene~~,~~ or alkenylene~~, :~~, or alkynl when Z is not present;

Formatted: Indent: Left 0 ch

Formatted: Subscript

Marked Up Pages


Z is -H, -OH, a substituted styrenyl, an aromatic ring, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein $R_3$ and $R_4$ are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, -c or a heterocyclic, or a heteroaryl moiety, or a cycloalkyl, or $R_3$ and $R_4$ together to form a heterocyclic ring, such as a morphorine; or Z is COOR wherein R is -H, $-CH_3$, $-C_nH_{2n+1}$, wherein (n = 2-4), or a cycloalkyl, when Y is not H;

X is a halo -F, -Cl, or -Br;

Y is H, when L is an alkylene, such as $-CH_2$, and Z is $-CONR_3R_4$, $R_3$ and $R_4$ are each -H and a hetercyclic or a heteroaryl, or a cycloalkyl, such as a cyclopentanyl; or Y is an short alkyl (C1-3), such as a methyl ($-CH_3$), or a halo -F, Cl, Br, and further wherein said pharmaceutical composition treats said subject suffering from said androgen receptor associated medical condition.

23.2. A pharmaceutical composior treating a subject suffering from an androgen receptor associated medical condition, comprising:

a compound according to formula VIII:




VIII


wherein:

$R_1$ and $R_2$ are each independently mono- or di-substituted groups, such as aselected from a methoxy group ($-OCH_3$), a hydroxyl group (-OH), or and an alkyl sulfonyl group, such as $-OSO_2C_2H_5$, $R_1$ and $R_2$ could be the same or different;

$R_3$ is selected from the group consisting of

Formatted: Subscript

Marked Up Pages



$R_4$ is selected from the group consisting of an alkyl~~$CH_3$, H,~~ and a halo~~F and Cl~~; and

n is 1 or 2.

wherein each phenyl of the compounds according to formula VI, VII, or VIII is mono- or di-substituted by $R_1$ or $R_2$.

~~; and~~

~~further wherein said pharmaceutical composition treats said subject suffering from said androgen receptor associated medical condition.~~

~~16.~~32. The pharmaceutical composition according to claim 1, ~~wherein said compound according to formula VI~~further comprising ~~comprises~~ a pharmaceutically acceptable carrier.

43. The pharmaceutical composition according to anyone of claims 1 or~~to 3~~ 2, ~~wherein said~~for use in the treatment of an androgen receptor associated medical condition selected from an unwanted immune response, an immune disorder, inflammation, acne, alopecia, hirsutism, a wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease) and cancer. ~~is an androgen receptor associated medical condition that is induced, caused or mediated by a normal or abnormal androgen receptor.~~

~~3. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is selected from an unwanted immune response, an immune disorder, inflammation.~~

Formatted: Indent: Left: 2.96 cm, First line: 0 cm, Line spacing: Multiple 1.15 li

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Marked Up Pages

4. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is, acne.

5. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is , alopecia, .

6. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is hirsutism.

7. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is , a wound.

8. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is , Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease).

9. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is , and cancer.

10 54. The pharmaceutical composition for use according to claim 1 3, wherein said androgen receptor associated medical conditioncancer is selected from prostate cancer, bladder cancer, liver cancer, breast cancer, pancreatic cancer, and ovarian cancer.

11. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is, bladder cancer.

12. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is, liver cancer.

13. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is, breast cancer.

Marked Up Pages

14. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is, pancreatic cancer.

15. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is, and ovarian cancer.

16. The pharmaceutical composition according to claim 1, wherein said compound according to formula VI comprises a pharmaceutically acceptable carrier.

17. The pharmaceutical composition according to claim 1, wherein said subject is human.

18. The pharmaceutical composition according to claim 1, wherein said subject is non-human.

19. The pharmaceutical composition according to claim 1, wherein said subject is a patient.


20. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is an unwanted immune response.

21. The pharmaceutical composition according to claim 1, wherein said androgen receptor associated medical condition is an immune disorder.

22. The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is provided in a therapeutically effective amount.

23. A pharmaceutical composition for treating a subject suffering from an androgen receptor associated medical condition, comprising:
a compound according to formula VIII:

Marked Up Pages




VIII

~~wherein:~~

~~$R_1$ and $R_2$ are mono- or di-substituted groups, such as a methoxy group (-$OCH_3$), a hydroxyl group (-OH), or an alkyl sulfonyl group, such as -$OSO_2C_2H_5$, $R_1$ and $R_2$ could be the same or different;~~

~~$R_3$ is selected from the group consisting of~~



~~$R_4$ is selected from the group consisting of $CH_3$, H, F and Cl;~~

~~n is 1 or 2; and~~

~~further wherein said pharmaceutical composition treats said subject suffering from said androgen receptor associated medical condition.~~

5~~24~~. Use of a pharmaceutical composition according to claim 1 in the manufacture of a medicament for A method of treating a subject suffering from an androgen receptor associated medical condition~~, comprising:~~

~~a) providing a subject; and~~

~~b) administering to said patient, a therapeutically effective amount of a compound according to claim 1, .~~

6. A compound of formula (VI):

Formatted: Indent: Hanging: 2.5 ch, Left 6 ch, First line: -2.5 ch


Formatted: Indent: Left 7.5 ch

Formatted: Indent: First line: 0 cm

Formatted: Indent: First line: 8.5 ch, Line spacing: Multiple 1.15 li

Formatted: Font: (Default) Arial, 10 pt

Marked Up Pages



(VI),

wherein

$R_1$ and $R_2$ are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;


L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein $R_3$ and $R_4$ are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or $R_3$ and $R_4$ together form a heterocyclic, and wherein X is a halo; or Z is COOR wherein R is -H, $-CH_3$, or a cycloalkyl; and

Y is an alkyl or a halo,

wherein each phenyl of the compound is mono- or di-substituted by $R_1$ or $R_2$.

7. A compound of formula VII:



VII

wherein $R_1$ and $R_2$ are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

L is a carbonyl, alkylene or alkenylene; or alkynl when Z is not present;

Z is -H, -OH, a substituted styrenyl, an aromatic ring, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein $R_3$ and $R_4$ are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or $R_3$ and $R_4$ together form a

Field Code Changed

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: First line: 11 ch

Formatted: Indent: First line: 0 cm, Left 8 ch

Formatted: Indent: Left 0 ch, First line: 10.5 ch

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: First line: 0 cm, Left 7.5 ch

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: Left 7.5 ch

Marked Up Pages


heterocyclic; or Z is COOR wherein R is -H, -$CH_3$, -$C_nH_{2n+1}$, wherein n = 2-4, or a cycloalkyl, when Y is not H;

X is a halo;

Y is H, an alkyl, or a halo,

wherein each phenyl of the compound is mono- or di-substituted by $R_1$ or $R_2$.

8. A compound according to formula VIII:




VIII

wherein:

$R_1$ and $R_2$ are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

$R_3$ is selected from the group consisting of



; and

$R_4$ is selected from the group consisting of an alkyl and a halo; and

n is 1 or 2,

wherein each phenyl of the compound is mono- or di-substituted by $R_1$ or $R_2$.

9. A compound of formula (VI):

Formatted: Indent: Left: 2.96 cm, Line spacing: Multiple 1.15 li


Formatted: Indent: Left 0 ch, First line: 8.5 ch

Formatted: Indent: Left 0 ch, First line: 8.5 ch

Formatted: Indent: First line: 8.5 ch

Formatted: Font: (Default) Arial, 10 pt

Marked Up Pages



(VI),

wherein

$R_1$ and $R_2$ are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;


Z is -H, -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein $R_3$ and $R_4$ are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or $R_3$ and $R_4$ together form a heterocyclic, and wherein X is a halo; or Z is COOR wherein R is -H, $-CH_3$, $-C_nH_{2n+1}$, wherein n = 2-4; and

Y is an alkyl,

wherein each phenyl of the compound is mono- or di-substituted by $R_1$ or $R_2$.

10. The compound of claim 9, wherein each of $R_1$ and $R_2$ is $-OCH_3$, L is an alkylene, Z is COOR, R being $-C_nH_{2n+1}$, wherein n = 2-4, and Y is an alkyl.

11 The compound of claim 9, wherein L and Z together form a group selected from



; and

Field Code Changed

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: First line: 11 ch

Formatted: Indent: First line: 0 cm, Left 6.5 ch

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: Left 6.5 ch

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: First line: 9 ch

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Indent: Left 6.5 ch

Formatted: Font: (Default) Arial, 10 pt


Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt

Formatted: Font: (Default) Arial, 10 pt


Marked Up Pages

12. The compound of claim 9, wherein the compound is



.

13. A compound of formula (VII):



(VII),

wherein

$R_1$ and $R_2$ are each independently selected from a methoxy group, a hydroxyl group, and an alkyl sulfonyl group;

L is a carbonyl, alkylene, or alkenylene, or alkynl when Z is not present;

Z is -H, -OH, a substituted styrenyl, a cycloalkyl, $-COR_3$, $-CONR_3R_4$, or $-CX_3$, wherein $R_3$ and $R_4$ are each –H, $-CH_3$, $-C_nH_{2n+1}$ wherein n = 2-4, a heterocyclic, a heteroaryl, or a cycloalkyl, or $R_3$ and $R_4$ together form a heterocyclic, and wherein X is a halogen; or Z is COOR wherein R is -H, $-CH_3$, $-C_nH_{2n+1}$, wherein n = 2-4; and

Y is an alkyl,


wherein each phenyl of the compound is mono- or di-substituted by $R_1$ or $R_2$.

14. The compound of claim 13, wherein each of $R_1$ and $R_2$ is $-OCH_3$, L is an alkylene, Z is COOR, R being $-C_nH_{2n+1}$, wherein n = 2-4, and Y is an alkyl.

Formatted: Justified, Indent: Left 6.5 ch
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Indent: First line: 8.5 ch
Formatted: Indent: First line: 0 cm, Left 6 ch
Formatted: Indent: First line: 8.5 ch
Formatted: Indent: First line: 0 cm, Left 6 ch
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Indent: Left 6 ch
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt

Marked Up Pages

15. The compound of claim 13, wherein L and Z together form a group selected from




16. A pharmaceutical composition for treating a subject suffering from an androgen receptor associated medical condition, the pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to one of Claims 9 to 15, wherein the androgen receptor associated medical condition is selected from inflammation, acne, alopecia, hirsutism, wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease), unwanted immune response, immune disorder, and cancer.

17. Use of a compound according to one of Claims 9 to 15 in the manufacture of a medicament for treating an androgen receptor associated medical condition, wherein the androgen receptor associated medical condition is selected from inflammation, acne, alopecia, hirsutism, wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease), unwanted immune response, immune disorder, and cancer.

18. Use of a compound according to one of Claims 6 to 8 in the manufacture of a medicament for treating an androgen receptor associated medical condition, wherein the androgen receptor associated medical condition is selected from

Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Indent: Left 6 ch, Font Alignment: Auto, Tab stops: Not at 0 cm + 0.72 cm
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt
Formatted: Font: (Default) Arial, 10 pt

Marked Up Pages

inflammation, acne, alopecia, hirsutism, wound, Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy's Disease), unwanted immune response, immune disorder, and cancer.

~~25. A method of treating a subject suffering from an androgen receptor associated medical condition, comprising:~~

~~a. providing a subject; and~~

~~b. administering to said patient, a therapeutically effective amount of a compound according to claim 23.~~

Formatted: Indent: Hanging: 1.5 ch, Left 6.5 ch, First line: -1.5 ch, Line spacing: 1.5 lines

Marked Up Pages